Pembrolizumab治疗MSI-H晚期胰腺癌的持久完全缓解

IF 0.6 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Clinical laboratory Pub Date : 2025-08-01 DOI:10.7754/Clin.Lab.2025.250144

Ali Türker, Mahmut Buyuksimsek, Irem K Türker, Mehmet Türker, Irfan Alisan

{"title":"Pembrolizumab治疗MSI-H晚期胰腺癌的持久完全缓解","authors":"Ali Türker, Mahmut Buyuksimsek, Irem K Türker, Mehmet Türker, Irfan Alisan","doi":"10.7754/Clin.Lab.2025.250144","DOIUrl":null,"url":null,"abstract":"Background: Pancreatic ductal adenocarcinoma remains a highly aggressive cancer with limited treatment options and poor prognosis. Pembrolizumab has shown potential in patients with micro satellite instability-high tumors. We report a rare case of complete remission of metastatic pancreatic cancer.Methods: A 58-year-old male with MSI-H advanced PDAC, who progressed during adjuvant and metastatic first-line treatment, was treated with pembrolizumab showed significant clinical improvement.Results: Pembrolizumab led to complete response. At the time of the report, the patient had durable response of 13 months.Conclusions: This case demonstrates the promising role of pembrolizumab in MSI-H advanced pancreatic cancer.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 8","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Durable Complete Response to Pembrolizumab in MSI-H Advanced Pancreatic Cancer.\",\"authors\":\"Ali Türker, Mahmut Buyuksimsek, Irem K Türker, Mehmet Türker, Irfan Alisan\",\"doi\":\"10.7754/Clin.Lab.2025.250144\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Pancreatic ductal adenocarcinoma remains a highly aggressive cancer with limited treatment options and poor prognosis. Pembrolizumab has shown potential in patients with micro satellite instability-high tumors. We report a rare case of complete remission of metastatic pancreatic cancer.Methods: A 58-year-old male with MSI-H advanced PDAC, who progressed during adjuvant and metastatic first-line treatment, was treated with pembrolizumab showed significant clinical improvement.Results: Pembrolizumab led to complete response. At the time of the report, the patient had durable response of 13 months.Conclusions: This case demonstrates the promising role of pembrolizumab in MSI-H advanced pancreatic cancer.\",\"PeriodicalId\":10384,\"journal\":{\"name\":\"Clinical laboratory\",\"volume\":\"71 8\",\"pages\":\"\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical laboratory\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.7754/Clin.Lab.2025.250144\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2025.250144","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：胰腺导管腺癌仍然是一种高度侵袭性的癌症，治疗选择有限，预后差。Pembrolizumab在微卫星不稳定性高的肿瘤患者中显示出潜力。我们报告一例罕见的转移性胰腺癌完全缓解的病例。方法：一名58岁男性MSI-H晚期PDAC患者，在辅助治疗和转移性一线治疗期间进展，经派姆单抗治疗后临床表现明显改善。结果：派姆单抗导致完全缓解。在报告时，患者有13个月的持续反应。结论：该病例证明了派姆单抗在MSI-H晚期胰腺癌中的良好作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Durable Complete Response to Pembrolizumab in MSI-H Advanced Pancreatic Cancer.

Background: Pancreatic ductal adenocarcinoma remains a highly aggressive cancer with limited treatment options and poor prognosis. Pembrolizumab has shown potential in patients with micro satellite instability-high tumors. We report a rare case of complete remission of metastatic pancreatic cancer.

Methods: A 58-year-old male with MSI-H advanced PDAC, who progressed during adjuvant and metastatic first-line treatment, was treated with pembrolizumab showed significant clinical improvement.

Results: Pembrolizumab led to complete response. At the time of the report, the patient had durable response of 13 months.

Conclusions: This case demonstrates the promising role of pembrolizumab in MSI-H advanced pancreatic cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical laboratory 医学-医学实验技术

CiteScore

1.50

自引率

0.00%

发文量

494

审稿时长

3 months

期刊介绍： Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.